Scrip asked 30 industry leaders to share their thoughts around what the biopharma industry will do – and what it needs to do – to advance diversity, equity and inclusion (DEI) this year. Their responses reflected the dual imperative to improve access to health for marginalized groups and to promote DEI within their own organizations and workforces.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion
Pharma Minds Focused On Access To Health Care And Research
The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.
